Fundamental Research has initiated coverage on Biome Grow (CSE:BIO) with a Buy rating and a fair value estimate of $1.25 per share. The report highlighted Biome Grow’s focus on the Atlantic provinces, stating that, “competition amongst LPs is less fierce,” and, “The company’s purposeful avoidance of Canada’s most LP dense provinces allows them to establish their brands across the Atlantic provinces, building a strong domestic base.” The report also higlighted the company’s supply agreement with Newfoundland, stating that it is, “one of the largest provincial supply agreements announced to date.”

Click here to access the report. 

As quoted in the Fundamental Research report:

With Biome, management intends to establish a cannabis business platform built upon risk-hedged production and a dominant presence in the Atlantic provinces. To hedge production risk, Biome has placed an emphasis on securing off-take and supply agreements prior to even beginning construction on production facilities, which they have successfully done in the province of Newfoundland.

On November 2, 2018, Biome secured a 24,000 kg, three-year supply agreement with the Newfoundland government, one of the largest provincial supply agreements to date. Note that multi-year supply agreements with provincial governments are exceptional, long-term economic agreements that are large-scale in nature and differ from provincial purchase orders. Provincial purchase orders are short-term, smaller orders made to secure near-term inventory, and almost all LPs receive provincial purchase orders on a recurring basis given short-term supply shortages. However, Biome’s supply agreement is one of only a rare few signed between an LP and a provincial government. in addition, the province agreed to issue Biome five retail storefront licenses, and we believe that there are very few provincial supply agreements that exhibit these features. The ability of Biome to secure such a significant contract, despite their relatively small size relative to other LPs, demonstrates the capability of Biome’s management, as well as the strength of Biome’s relationship with Atlantic Canada.


Click here to connect with Biome Grow Inc. (CSE:BIO) for an Investor Presentation.


Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info:

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less